PharmaTher secures U.S. patent for ketamine in ALS

PharmaTher (PHRRF) Holdings announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,128,012, expiring May 14, 2041, for the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis. This newly issued patent significantly strengthens the Company’s intellectual property portfolio and provides robust protection for its clinical development program for ketamine in ALS. This achievement complements PharmaTher’s existing Orphan Drug Designation for ketamine, granted by the U.S. Food and Drug Administration, creating a powerful strategic advantage in addressing this devastating neurodegenerative disease.